Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Romiplostim (Nplate)14 residuesIEGPTLRQWLAARAEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Nplate, AMG 531
A 79% platelet response rate in the important RCT, versus zero on placebo. Romiplostim (Nplate) is a peptibody, an Fc-peptide fusion protein that mimics thrombopoietin and tells the bone marrow to produce more platelets. It earned FDA approval for immune thrombocytopenia (ITP) and carries over five years of long-term safety data. Bone marrow reticulin deposition shows up in roughly 10% of treated patients, though changes reverse after stopping treatment. ITP patients who've exhausted corticosteroids, IVIg, or splenectomy turn to romiplostim for reliable, dose-dependent platelet recovery within one to two weeks.
Romiplostim (marketed as Nplate by Amgen) is an Fc-peptide fusion protein that activates the thrombopoietin receptor to drive platelet production. The 2008 Lancet trial (n=125)[1] delivered the headline result: 79% responded versus zero on placebo. Romiplostim is built from two identical subunits. Each is an Fc-peptide fusion built from two identical subunits. Each subunit pairs a human IgG1 Fc domain with a peptide carrying two thrombopoietin receptor (c-Mpl) binding domains. The result is a molecule that activates the same receptor as endogenous thrombopoietin, triggering megakaryocyte proliferation and platelet production in the bone marrow. Critically, romiplostim shares no amino acid sequence homology with natural TPO. That design choice reduces the risk of cross-reactive antibodies. In practice, this is a drug for ITP patients who've already tried and failed corticosteroids, IVIg, or splenectomy. FDA approval covers adults and pediatric patients aged one year and older. Dosing starts at 1 mcg/kg subcutaneously once weekly. Clinicians titrate upward in 1 mcg/kg steps, guided by weekly CBC results, until platelets reach at least 50 x 10^9/L. The ceiling is 10 mcg/kg per week. Long-term data from Kuter and colleagues [2] tracked patients beyond five years and found durable efficacy without new safety signals. About 32% of patients in Phase II data achieved sustained treatment-free remission after dose tapering. The cost, however, is staggering: $5,400 to $11,300 per month without insurance. Amgen's SupportPlus co-pay program and patient assistance options help offset that burden, and roughly 70% of claims show zero out-of-pocket cost.
Romiplostim binds to and activates the thrombopoietin receptor (c-Mpl) on megakaryocyte precursors in bone marrow. That receptor activation kicks off the JAK2/STAT5 and MAPK signaling cascades downstream. The practical effect is straightforward. Megakaryocytes proliferate, differentiate, and mature faster. More megakaryocytes means more platelets released into circulation. Platelet count increases are dose-dependent and typically measurable within one to two weeks of starting treatment. The molecular architecture matters here. Romiplostim is a peptibody: two identical single-chain subunits, each containing a human IgG1 Fc domain fused to a peptide with two c-Mpl binding domains. The Fc portion extends the half-life (median 3.5 days) by engaging neonatal Fc receptors for recycling. The dual binding domains on each subunit increase receptor activation potency. One feature separates romiplostim from recombinant TPO therapies that were abandoned in the early 2000s. Romiplostim has zero amino acid sequence homology with endogenous thrombopoietin. Earlier recombinant TPO products triggered neutralizing antibodies that cross-reacted with the patient's own TPO, causing paradoxical thrombocytopenia. By using a novel peptide sequence that binds the same receptor through a different structural interface, romiplostim avoids that antibody cross-reactivity problem entirely.
Romiplostim is an FDA-approved thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP). The Lancet 2008 RCT (n=125)[1] demonstrated a 79% platelet response rate vs. 0% placebo. Five-year long-term safety data confirmed durable efficacy without new safety signals. Bone marrow reticulin deposition occurs in ~10% of patients; collagen fibrosis in ~2% biopsied (reversible on discontinuation). Rebound thrombocytopenia risk post-discontinuation is well-characterized. No head-to-head RCT vs. eltrombopag. MDS exclusion required: blast progression risk documented.
Kuter DJ et al. Lancet 2008 (PMID 18242413): double-blind RCT n=125; 79% platelet response rate vs 0% placebo in ITP patients
Bone marrow reticulin deposition in ~10% of patients; collagen fibrosis in ~2% biopsied (reversible on discontinuation). Rebound thrombocytopenia risk post-discontinuation. No head-to-head RCT vs eltrombopag. MDS exclusion required: blast progression risk.
Considered reliable and effective by ITP patients for platelet stabilization. High cost and weekly injection burden are the dominant complaints. Rebound thrombocytopenia fear drives reluctance to attempt discontinuation.
Community use is strictly on-label (ITP treatment under physician supervision). No off-label wellness or performance use observed. Patient-reported outcomes (~80% responders) match published RCT data. Cost and post-injection side effect burden are patient concerns not emphasized in FDA label language.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mcg | Weekly |
| Moderate | 3mcg | Weekly |
| Aggressive | 10mcg | Weekly |
Romiplostim is weight-based dosing, so the math changes for every patient. Start at 1 mcg/kg weekly. For a 70 kg person, that's 70 mcg. Reconstitution: add 0.72 mL of sterile water for injection to a 250 mcg vial. That gives you 500 mcg/mL. Swirl gently; don't shake it. Let the vial sit about five minutes until the solution is clear and colorless. Syringe math for a 70 kg patient on a U-100 insulin syringe at 500 mcg/mL: 70 mcg equals 0.14 mL, which is 14 units. At 3 mcg/kg (210 mcg), you'd pull 42 units. At the max dose of 10 mcg/kg (700 mcg), that's 140 units, so you'd need a 500 mcg vial reconstituted with 1.2 mL sterile water (also yielding 500 mcg/mL). Don't pool unused portions from multiple vials. The FDA label explicitly prohibits it. Single-use only; discard what's left. Store reconstituted solution at room temperature or refrigerated, but use it within 24 hours.
Romiplostim is administered continuously as long-term maintenance therapy, not cycled. Dose is titrated weekly by 1 mcg/kg increments based on platelet counts, starting at 1 mcg/kg. Target platelet count is ≥50 × 10⁹/L. Maximum dose is 10 mcg/kg/week. Do not abruptly discontinue: rebound thrombocytopenia may occur.
Romiplostim is continuous long-term maintenance therapy, not a cycled compound. Cycling rationale does not apply. Dose adjustments are driven solely by platelet counts (CBC-guided weekly titration). Discontinuation is pursued when sustained remission is the goal (typically after ≥12 months stable response) or when therapy fails: never by a predetermined off-cycle schedule. There is no receptor desensitization, hormonal axis, or antibody formation rationale for cycling romiplostim.
Or use the universal Peptide Calculator for any peptide.
Expected: ~80% of ITP patients achieve platelet count ≥50 × 10⁹/L. Platelet response typically begins within 1–2 weeks. Phase II data: ~32% achieve sustained treatment-free remission after dose tapering. Pediatric real-world cohort 2024: 83% overall response rate.
Monitor: CBC with differential weekly during titration → monthly once stable. Peripheral blood smear monthly. Bone marrow biopsy if smear shows new/worsening morphological abnormalities. Weekly CBC for ≥2 weeks post-discontinuation (rebound risk).
Weigh yourself or confirm your current weight with your prescribing physician. The dose is calculated as mcg per kg of body weight.
Reconstitute a 250 mcg vial by adding 0.72 mL of sterile water for injection. For a 500 mcg vial, add 1.2 mL. Both yield a concentration of 500 mcg/mL.
Do not shake. Let it sit for about five minutes until the solution turns clear and colorless. If it's cloudy or contains particles, do not use it.
Example: 70 kg patient at 1 mcg/kg needs 70 mcg. At 500 mcg/mL, that's 0.14 mL, which reads as 14 units on a U-100 insulin syringe.
Draw the calculated volume using a 27- to 29-gauge insulin syringe. Remove air bubbles by tapping the syringe and pushing gently.
Rotate injection sites each week.
Evening dosing can help you sleep through post-injection headache and myalgia.
Do not save or pool unused portions.
Store unused vials at 2 to 8 degrees Celsius, protected from light. Do not freeze. Use reconstituted solution within 24 hours.
Once platelets are stable at 50 x 10^9/L or above for four consecutive weeks, monitoring can extend to monthly.
Often continued at reduced dose during romiplostim initiation. Taper as platelets stabilize: this is concurrent standard-of-care ITP therapy, not a peptide stack.
Gradual steroid taper as platelet counts reach and maintain ≥50 × 10⁹/L
Second TPO receptor agonist: overlapping mechanism risks supranormal platelet counts and dangerous thrombocytosis. FDA label explicitly contraindicates combination. Switch with washout period if changing agents.
Do not combineAll TPO receptor agonists share the same mechanism. Combining any two TPO-RAs is contraindicated: uncontrolled platelet overproduction risk.
Do not combinePricing updated 2026-04-09
Bone marrow reticulin fiber deposition is the safety concern that gets the most attention. Published data show reticulin changes in roughly 10% of treated patients. Collagen fibrosis, the more serious form, appears in about 2% of those biopsied. The reassuring part: these changes have reversed on discontinuation in published cases. The FDA label requires monthly peripheral blood smears to catch early morphological changes (teardrop cells, nucleated red blood cells). If a smear looks abnormal, bone marrow biopsy follows. Rebound thrombocytopenia after stopping romiplostim is a real risk, not a theoretical one. Platelet counts can drop below the pre-treatment baseline within two weeks of the last dose. The FDA label mandates weekly CBC monitoring for at least two weeks post-discontinuation. ITP patient communities discuss this extensively; the fear of rebound is a primary reason patients hesitate to attempt discontinuation even after months of stable counts. Thrombocytosis is the opposite problem. Platelet counts can overshoot into a dangerous range above 400 x 10^9/L, raising thromboembolism risk. The protocol is clear: hold the dose for one week, then reduce by 1 mcg/kg. If counts stay raised above 400 on two consecutive readings after dose reduction, discontinue. For patients with myelodysplastic syndromes (MDS), romiplostim carries a specific warning. Blast progression has been documented. MDS must be excluded before starting treatment, and any non-responding patient at maximum dose should be reassessed for an underlying malignancy rather than assuming dose insufficiency. Day-to-day side effects are dominated by headache (35% incidence), arthralgia (26%), dizziness (17%), insomnia (16%), and myalgia (14%). Community reports consistently describe headaches and joint or muscle pain peaking 24 to 48 hours after injection. Scheduling the dose for evenings allows sleeping through the worst of it. Abdominal pain (11%), shoulder pain (8%), and paresthesia (6%) round out the common profile. Neutralizing antibodies to romiplostim or endogenous TPO are rare but monitored. Pregnancy is Category C; use only if the potential benefit justifies fetal risk. Romiplostim should not be used for portal hypertension-related thrombocytopenia, which is not ITP.
Verify Romiplostim (Nplate) dosing and safety with a second opinion
FDA-approved biologic from Amgen, manufactured under GMP. Single-use lyophilized vials with verified potency. Risk is negligible when obtained through licensed pharmacy channels. Risk becomes high if sourced from unregulated gray-market or unauthorized compounders: authenticity and potency of biologics cannot be verified outside licensed supply chain.
| Test | When | Target |
|---|---|---|
| CBC with differential | Weekly during initiation and titration; monthly once platelets stable ≥50 × 10⁹/L for ≥4 consecutive weeks | Platelets 50–200 × 10⁹/L (reduce if >200; hold/reduce if >400) |
| Peripheral blood smear | Monthly throughout treatment | — |
| Bone marrow biopsy | If peripheral blood smear shows new or worsening morphological abnormalities | — |
| Platelet count: post-discontinuation monitoring | Weekly for ≥2 weeks after stopping romiplostim | — |
Primary efficacy and safety endpoint. Drives all dose adjustments. Detects thrombocytosis (>200 triggers reduction; >400 triggers hold).
FDA label requirement: detects morphological abnormalities (teardrop cells, nucleated RBCs) signaling possible bone marrow fibrosis or MDS progression.
Confirms or excludes reticulin/collagen fiber deposition. Changes are reversible on discontinuation in published cases.
Rebound thrombocytopenia risk. Platelet counts may drop below pre-treatment baseline in the 2 weeks following discontinuation.
Initiate at 1 mcg/kg weekly; baseline CBC obtained; platelet response not yet expected
Platelet counts begin to rise; dose titrated weekly by 1 mcg/kg based on response
Majority of responders achieve target platelet count ≥50 × 10⁹/L; concurrent ITP medications may begin tapering
Stable platelet counts maintained; dose adjustments become less frequent; monitoring interval may extend to monthly
Durable long-term response; some patients may achieve sustained remission allowing dose reduction
Week 1: The first dose goes in at 1 mcg/kg. Don't expect platelet numbers to budge yet. Most patients report headache and flu-like symptoms 24 to 48 hours after that initial injection. Baseline CBC is your starting reference point. Weeks 2 to 4: Platelet counts start climbing. Weekly blood draws guide dose increases of 1 mcg/kg at a time. Patients in r/ITP describe real relief when they see counts moving upward for the first time. Post-injection headache and myalgia typically ease up by weeks three and four. Weeks 4 to 8: Most responders hit the target of 50 x 10^9/L platelets by this point. Bruising decreases. Bleeding anxiety drops. Corticosteroid tapering can begin, and for patients who've been on chronic prednisone, that milestone alone feels transformative. Months 3 to 6: Stable platelet counts on a steady dose. CBC monitoring can shift from weekly to monthly. Dose reduction trials may start to test whether remission is possible. The weekly injection routine is established; patients describe it as manageable but tiring over months. Months 6 to 12 and beyond: About 32% of patients in Phase II data achieved sustained treatment-free remission after careful dose tapering. Five-year safety data from Kuter and colleagues [2] confirmed continued efficacy without new safety signals. Reticulin deposition monitoring continues. Patients who attempt discontinuation do so cautiously, with weekly platelet checks and significant anxiety about rebound. Some community members report years-long stable remission after stopping.
First 1 mcg/kg dose administered. No measurable platelet count change expected within the first 7 days.
Most patients feel no platelet benefit at week 1. Headache and flu-like symptoms commonly reported 24–48 hours after first injection.
Measurable platelet count increases. Weekly CBC guides 1 mcg/kg incremental dose adjustments.
Patients describe relief at first rising counts. Anxiety around each weekly lab is common. Post-injection side effects typically diminish in severity by weeks 3–4.
Majority of responders reach platelet count ≥50 × 10⁹/L. Concurrent corticosteroid tapering may begin.
Patients report "life returning to normal": reduced bruising, less bleeding anxiety. Steroid tapering is a major milestone for this group.
Durable platelet response with stable dose. CBC monitoring can extend to monthly. Dose reduction trials initiated in some patients.
Weekly injection routine is established but reported as a burden. Cost burden and insurance navigation are dominant concerns at this stage.
~32% achieve sustained treatment-free remission after dose tapering (Phase II data). 5-year safety data: continued efficacy without new safety signals. Reticulin deposition monitoring ongoing.
Patients who attempt discontinuation do so cautiously with weekly platelet monitoring. Rebound thrombocytopenia is a major fear discussed extensively in r/ITP. Some report years-long stable treatment-free remission.
Source: Wang B et al. Clin Pharmacokinet. 2010;49(10):655-665. Median terminal half-life ~3.5 days (range 1-34 days).
Loading the interactive decay curve.
Romiplostim (Nplate) holds FDA approval for the treatment of immune thrombocytopenia (ITP) in adults and pediatric patients one year and older who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. The original NEXUS REMS program required provider and patient enrollment; FDA relaxed those requirements in December 2011 after post-marketing safety data matched the clinical trial profile. Healthcare providers no longer need separate registration to prescribe romiplostim. Nplate is manufactured by Amgen and distributed through specialty pharmacies. It is a biologic product and should only be obtained through licensed pharmacy channels. Gray-market or compounded versions of romiplostim cannot be verified for potency or authenticity. Romiplostim is not listed on the WADA prohibited substances list, but athletes undergoing doping controls should disclose all medications to their governing body. This content is for informational purposes only and does not constitute medical advice. Romiplostim requires a prescription and physician supervision, including regular blood count monitoring.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
